Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure

Inclusion Criteria

• •Male or female ≥ 18 years of age, with body weight ≤ 160 Kg
• •Diagnosis of stable CHF:
• •* New York Heart Association (NYHA) functional Class II/III.
• •* Receiving guideline-recommended treatment for CHF.
• •Left ventricular ejection fraction \< 45%, obtained within the last 3 months prior to screening.
• •NT-proBNP \> 300 ng/L in sinus rhythm or \> 900 ng/L if not in sinus rhythm (determined locally).
• •Ability to exercise for at least 10 to 12 minutes based on investigator's judgment.
• •Systolic BP ≥ 125 mmHg at randomization
• •Renal function defined as an eGFR of ≥ 25 mL/min/1.73 m\^2 at screening (sMDRD formula).